REG - Johnson Matthey PLC - Completion of Medical Device Components sale

Johnson MattheyAnnouncement

01/07/2024 14:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240701:nRSA5829Ua&default-theme=true

RNS Number : 5829U  Johnson Matthey PLC  01 July 2024

Johnson Matthey announces completion of Medical Device Components sale
1(st) July 2024

 

 

 Further to the announcement on 20(th) March 2024, Johnson Matthey Plc (JM) is
 pleased to announce that it has today completed the sale of its Medical Device
 Components business (MDC) in accordance with the terms of the sale agreement
 entered into between JM and Montagu Private Equity for cash consideration of
 US$700 million (£550 million) on a cash free debt free basis.

 The board confirms its intention to return £250 million of the net proceeds
 from the sale of MDC by way of an on-market share buyback programme. This will
 commence later this week and further details will be announced in due course.

 ENDS

 

 

 Enquiries:
 Investor Relations
 Martin Dunwoodie    Director of Investor Relations and Treasury  +44 20 7269 8241

 Louise Curran       Head of Investor Relations                   +44 20 7269 8235
 Chris Wood          Senior Investor Relations Manager            +44 20 7269 8138
 Media
 Sinead Keller       Group External Relations Director            +44 20 7269 8218

 Harry Cameron       Teneo                                        +44 7799 152148

 

 Johnson Matthey Plc is listed on the London Stock Exchange (JMAT)
 Registered in England & Wales number: 00033774
 Legal Entity Identifier number: 2138001AVBSD1HSC6Z10

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DISSSDSAFELSELW